IV Administration of ChromaDex's Niagen® as Compared to NAD+

What Was Tested

The trial (not phased) is built around NAD+.

This is a 2-part study evaluating the effects of IV administration of NR on healthy adult populations.

Study 1 involved all four arms with 37 people.

The second study only included the active NR and NAD+ arms to further evaluate tolerability and comfort of the IV.

It had four arms (groups): NR (Cohorts 1&2) (experimental), Active Comparator (Cohorts 1&2) (active comparator), Oral Comparator (Cohort 1 only) (other) and Placebo (Cohort 1 only) (placebo comparator).

The registry classes the interventions as dietary supplement and other.

Who Took Part

Enrollment: 53 actual participants took part.

It was open to people of any sex aged from 40 years with no upper age limit.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Provision of signed and dated informed consent form. Lives within 100 miles of a NRI study site. Any gender, aged 40+ (For the 5th arm, only males will be evaluated.). Good general health as evidenced by medical history. Agreement to adhere to Lifestyle Considerations throughout study duration.

The full record lists 7 inclusion and 7 exclusion criteria; among the exclusions: current diagnosis of any seizure disorder, diabetes or insulin resistance, any kidney or liver disorder, heart disease, cancer, or parkinson's disease,; pregnancy, trying to conceive, or breastfeeding; known allergic reactions to any components of the intervention.

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

Random assignment meant chance, not the researchers, decided who got NAD+ and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received NAD+.

Those kept unaware of assignments: participant and care provider.

It started in 2023-11-13 with completion listed for 2024-03-08.

It ran at 1 site in United States.

Its stated primary purpose is other.

What Was Measured

The main thing measured (primary outcome): Blood Pressure. Heart rate. Total NAD measured through dried blood spot testing.

It also tracked 4 secondary outcomes, for example Complete Blood Count, Comprehensive Metabolic Panel, Sleep Scale and Energy Scale.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of NAD+ in 53 people.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.